Istari Oncology
  • About Us
    • Management Team
    • Board of Directors
  • Our Science
    • PVS-RIPO
    • ADC
    • Publications
  • Pipeline
    • Clinical Trials
    • Expanded Access
    • Therapeutic Areas
  • News
  • Contact Us
Press enter to begin your search
  • About Us
    • Management Team
    • Board of Directors
  • Our Science
    • PVS-RIPO
    • ADC
    • Publications
  • Pipeline
    • Clinical Trials
    • Expanded Access
    • Therapeutic Areas
  • News
  • Contact Us

Publications


Here we provide links to some of the key peer-reviewed publications behind the discovery and development of our immunotherapy technologies for glioblastoma multiforme (GBM) and other solid tumor cancers.

When viruses attack- Nature Reviews: Cancer, October 2017.

Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLs- Science Translational Medicine, Sept. 2017.

Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models- Oncotarget, Oct. 2016.

Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus – Discovery Medicine, May 2015.

Induction of viral, 7-methyl-guanosine Cap-Independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase – Journal of Virology, Nov 2014.

Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis – Journal of Virology, March 2012.

Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype – Molecular Therapy, Nov 2008.

Intergeneric poliovirus recombinants for the treatment of malignant glioma – PNAS, June 2000.

 

About Istari Oncology

Istari Oncology, Inc. is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. The Company was founded in 2016 to continue research and clinical development of technology discovered at Duke University.

Addresses

Physical Address:
6 Davis Drive
Research Triangle Park, NC  27709

Mailing Address:
P.O. Box 2896
Chapel Hill, NC  27515

Contact Information

(919) 245.7662
info@istarioncology.com

Site Usage

Privacy Policy
Terms of Use

©2017 - Istari Oncology, Inc.